We need new therapeutic approaches above and beyond the anti-amyloid drugs if we are to meaningfully impact AD progression and need to be able to test these when the evidence supports. Prof Tara Spires-Jones , Director of the Centre for Discovery Brain Sciences at the University of Edinburgh, Group Leader at the UK DRI at Edinburgh, and Past President of the British Neuroscience Association said: Novo Nordisk reported that semaglutide failed to slow the progression of Alzheimers disease in two well-conducted phase III clinical trials
35 Similarly, in a recent study of obese individuals without diabetes, Louis et al demonstrated that tirzepatide (10 or 15 mg) resulted in significantly greater weight loss than semaglutide (1.7 or 2.4 mg) over a 72-week period
Florence Nightingale J
This reaction is accelerated by heat and by acidic or basic pH extremes
While genetic data does not predict exact medication response or injection tolerance, understanding your individual genetic profile may help your provider tailor preparation strategies and dosing approaches that align with your physiological predispositions
If you are taking Saxenda, you can easily switch to Wegovy weight loss pen
